Protara Therapeutics

TARA · NASDAQ

$2.56+$0.23 (+9.87%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.33

TARA analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $26.18 (+922.7% upside)

Low: $20.20
Now: $2.56
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

TARA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Oppenheimer	May 20, 2026	Maintains	Outperform	$25.00 → $28.00	45%
JP Morgan	May 14, 2026	Maintains	Overweight	$27.00 → $26.00	40%
HC Wainwright & Co.	Apr 29, 2026	Maintains	Buy	$23.00 → $27.00	54%
JP Morgan	Mar 4, 2026	Initiates	Overweight	$27.00	40%
HC Wainwright & Co.	Feb 10, 2026	Maintains	Buy	$23.00	41%
Piper Sandler	Jan 7, 2026	Initiates	Overweight	$24.00	70%
HC Wainwright & Co.	Dec 3, 2025	Maintains	Buy	$23.00	41%
HC Wainwright & Co.	Nov 19, 2025	Maintains	Buy	$23.00	41%

The case for and against

Updated May 26, 2026

Bull case

Protara Therapeutics is positioning itself for future success with a pragmatic approach to label expansion, robust pipeline with upcoming data releases, and a clear value proposition for its lead candidate TARA-002 in NMIBC and rare diseases. Their emphasis on real-world adoption, ease-of-administration advantage, and nonoverlapping toxicity profile sets it apart in the market and could lead to significant market share and revenue potential. The BCG supply shortage could also work to their advantage in expediting trial enrollment and providing larger datasets for TARA-002's efficacy and durability. However, questions remain regarding the control arm of the registrational study, benchmarking against BCG standard of care, and statistical powering for each comparator arm.

Bear case

Protara Therapeutics is heavily dependent on the success of its two lead product candidates, TARA-002 and IV Choline Chloride, for its future growth and profitability potential. However, the company faces significant challenges in terms of competition, regulatory and clinical development risks, as well as potential supply shortages and financial hurdles. While the company has a solid potential for long-term growth, its near-term outlook is uncertain and investors should approach with caution.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.